Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-07-12
|
ODS2004436 |
lung cancer |
1 |
Oncodesign (France) |
Cancer - Oncology |
2016-07-12
|
EBV-CTL |
EBV-Associated lymphomas and lymphoproliferative disorders |
N/A |
Atara Biotherapeutics (USA - CA) |
Cancer - Oncology - Transplantation |
2016-07-11
|
MYK-461 |
hypertrophic cardiomyopathy |
1 |
Myokardia (USA - CA) |
Cardiovascular diseases |
2016-07-11
|
CDX-014 |
advanced renal cell carcinoma (RCC). |
1-2 |
Celldex Therapeutics (USA - NJ) |
Cancer - Oncology |
2016-07-11
|
masitinib |
amyotrophic lateral sclerosis |
preclinical |
AB Science (France) |
Rare diseases - Neurodegenerative diseases |
2016-07-09
|
Vacc-4x and Istodax® (romidepsin) |
HIV infection |
1-2 |
Bionor Pharma (Norway) Celgene (USA - NJ) |
Infectious diseases |
2016-07-09
|
ARC-521 |
chronic hepatitis B |
1-2 |
Arrowhead Research Corporation (USA - CA) |
Infectious diseases |
2016-07-08
|
CCP-08 |
cough cold |
preclinical |
Vernalis (UK) Tris Pharma (USA - NJ) |
Respiratory diseases |
2016-07-08
|
roxadustat |
anemia associated with chronic kidney disease (CKD) |
2 |
FibroGen (USA - CA) |
Kidney diseases - Renal diseases |
2016-07-08
|
Sutent® (sunitinib) |
patients with renal cell carcinoma (RCC) who are at high risk for recurrence after surgery |
3 |
Pfizer (USA - NY) |
Cancer - Oncology |
2016-07-07
|
dual orexin receptor antagonist (DORA) |
insomnia |
2 |
Actelion (Switzerland) |
CNS diseases |
2016-07-07
|
Zika virus vaccine |
Zika virus infection |
|
Valneva (France- Austria) |
Infectious diseases |
2016-07-07
|
Soliris® (eculizumab) |
refractory generalized myasthenia gravis (MG) |
3 |
Alexion Pharmaceuticals (USA - CT) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2016-07-07
|
ALN-HBV |
Hepatitis B iInfection |
1-2 |
Alnylam Pharmaceuticals (USA - MA) |
Infectious diseases |
2016-07-07
|
LusiNEX, biosimilar version of RoActemra® (tocilizumab) |
rheumatoid arthritis |
1 |
Mycenax Biotech (Taiwan) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-07-06
|
CDKL5 program |
cyclin-dependent kinase-like 5 (CDKL5) deficiency |
preclinical |
Amicus Therapeutics (USA - NJ) |
Rare diseases - Genetic diseases - Neurological diseases |
2016-07-06
|
pediatric formulation of Opsumit® (macitentan) |
pulmonary arterial hypertension |
3 |
Actelion (Switzerland) |
Rare diseases - Cardiovascular diseases - Autoimmune diseases |
2016-07-06
|
AZD4635 ( HTL1071) and durvalumab (MEDI4736) |
advanced solid malignancies, non small cell lung cancer |
1 |
AstraZeneca (UK) |
Cancer - Oncology |
2016-07-06
|
MM-151 |
advanced solid tumors, colorectal cancer, squamous cell head and neck cancer, non small cell lung cancer, triple negative breast cancer |
1 |
Merrimack Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2016-07-06
|
avelumab (MSB0010718C) |
ovarian cancer |
3 |
Pfizer (USA - NY) Merck KGaA (Germany) |
Cancer - Oncology |